Hyperhomocysteinemia in Cardiovascular Diseases: Revisiting Observational Studies and Clinical Trials
- PMID: 36170884
- DOI: 10.1055/a-1952-1946
Hyperhomocysteinemia in Cardiovascular Diseases: Revisiting Observational Studies and Clinical Trials
Abstract
Thromboembolic manifestations are relatively frequent in patients with intermediate/severe hyperhomocysteinemia (>30 µmol/L) related to inherited disorders and deficiencies in vitamin B12 and folate. In contrast, moderate hyperhomocysteinemia (15-30 µmol/L) is a modest predictor of cardiovascular risk. The recognition of homocysteine as a cardiovascular risk factor has been challenged by some but not all randomized clinical trials. We reviewed the main data of this controversy and formulated conclusions to be translated in clinical practice.Homocysteine-lowering trials have been performed in cardiovascular subjects with moderate but not intermediate/severe hyperhomocysteinemia despite the dose-effect risk association. The first meta-analyses found no benefit and led cardiology societies not recommending homocysteine in the assessment of cardiovascular risk. This guideline challenged the need to diagnose and treat the nutritional and genetic causes of intermediate/major hyperhomocysteinemia and was not revised when larger meta-analyses concluded to a reduced risk of stroke. In a recent observational study, 84% of consecutive cardiovascular patients assessed for homocysteine had intermediate or major hyperhomocysteinemia, which was properly assessed in only half of the cases and related to B12 and/or folate deficiency and Addison/Biermer disease in 55% of these cases.In conclusion, revisiting observational studies and clinical trials suggests that cardiovascular patients should be screened for hyperhomocysteinemia, when no other risk factor is found. Patients with intermediate/major hyperhomocysteinemia should be properly assessed and treated for B vitamin deficiencies and inherited disorders according to current guidelines. Further trials are needed to assess the effect of lowering homocysteine according to hyperhomocysteinemia categories at baseline.
Thieme. All rights reserved.
Conflict of interest statement
None declared.
Similar articles
-
Cardiovascular manifestations of intermediate and major hyperhomocysteinemia due to vitamin B12 and folate deficiency and/or inherited disorders of one-carbon metabolism: a 3.5-year retrospective cross-sectional study of consecutive patients.Am J Clin Nutr. 2021 May 8;113(5):1157-1167. doi: 10.1093/ajcn/nqaa432. Am J Clin Nutr. 2021. PMID: 33693455
-
DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.Clin Chem Lab Med. 2003 Nov;41(11):1392-403. doi: 10.1515/CCLM.2003.214. Clin Chem Lab Med. 2003. PMID: 14656016 Review.
-
Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.Z Kardiol. 2004 Jun;93(6):439-53. doi: 10.1007/s00392-004-0075-3. Z Kardiol. 2004. PMID: 15252738 Review.
-
Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.Semin Thromb Hemost. 2000;26(3):341-8. doi: 10.1055/s-2000-8101. Semin Thromb Hemost. 2000. PMID: 11011852 Review.
-
Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.J Nephrol. 2003 Jul-Aug;16(4):522-34. J Nephrol. 2003. PMID: 14696754 Clinical Trial.
Cited by
-
Homocysteine Metabolism, Subclinical Myocardial Injury, and Cardiovascular Mortality in the General Population.JACC Asia. 2024 Jul 9;4(8):609-620. doi: 10.1016/j.jacasi.2024.05.005. eCollection 2024 Aug. JACC Asia. 2024. PMID: 39156513 Free PMC article.
-
Relationship between exposure to fine particulate matter and cardiovascular risk factors and the modifying effect of socioeconomic status: a cross-sectional study in Beijing, China.Front Public Health. 2024 Jul 19;12:1398396. doi: 10.3389/fpubh.2024.1398396. eCollection 2024. Front Public Health. 2024. PMID: 39100956 Free PMC article.
-
Preventing hyperhomocysteinemia using vitamin B6 supplementation in Givosiran-treated acute intermittent porphyria: Highlights from a case report and brief literature review.Mol Genet Metab Rep. 2024 Apr 4;39:101076. doi: 10.1016/j.ymgmr.2024.101076. eCollection 2024 Jun. Mol Genet Metab Rep. 2024. PMID: 38601120 Free PMC article.
-
Hypothyroidism and Cardiovascular Disease: A Review.Cureus. 2024 Jan 18;16(1):e52512. doi: 10.7759/cureus.52512. eCollection 2024 Jan. Cureus. 2024. PMID: 38370998 Free PMC article. Review.
-
Diet-Induced Severe Hyperhomocysteinemia Promotes Atherosclerosis Progression and Dysregulates the Plasma Metabolome in Apolipoprotein-E-Deficient Mice.Nutrients. 2024 Jan 23;16(3):330. doi: 10.3390/nu16030330. Nutrients. 2024. PMID: 38337615 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources